[{"id":"b6f71eec-7809-4305-ba8a-5033e44f0df2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05228600","created_at":"2022-02-12T17:48:00.959Z","updated_at":"2024-07-02T16:36:10.084Z","phase":"Phase 1","brief_title":"YL-13027 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05228600","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-13027"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 05/17/2022","start_date":" 05/17/2022","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-05-20"}]